Outcomes

cg25365794

cg08862778


HR (95% CI)*

HR (95% CI)*


Overall incident cancer^{#}

Tertile 1

Ref.

Ref.

Tertile 2

0.77 (0.59, 1.01)

0.93 (0.71, 1.21)

Tertile 3

0.90 (0.68, 1.18)

0.84 (0.62, 1.12)

Increase per 1 SD

0.98 (0.87, 1.10)

0.99 (0.87, 1.12)

Incident lung cancer^{†}

Tertile 1

Ref.

Ref.

Tertile 2

0.73 (0.46, 1.16)

0.90 (0.57, 1.41)

Tertile 3

0.78 (0.48, 1.27)

0.67 (0.40, 1.11)

Increase per 1 SD

0.81 (0.66, 0.99)

0.94 (0.77, 1.15)

Incident colorectal cancer^{†}

Tertile 1

Ref.

Ref.

Tertile 2

0.72 (0.43, 1.19)

1.07 (0.65, 1.76)

Tertile 3

0.83 (0.50, 1.40)

1.46 (0.88, 2.44)

Increase per 1 SD

0.98 (0.79, 1.21)

1.16 (0.96, 1.41)

Incident breast cancer^{‡} (in female participants)

Tertile 1

Ref.

Ref.

Tertile 2

0.91 (0.55, 1.51)

0.67 (0.40, 1.11)

Tertile 3

0.91 (0.50, 1.65)

0.57 (0.33, 0.97)

Increase per 1 SD

0.90 (0.70, 1.16)

0.84 (0.63, 1.11)

Incident prostate cancer^{#}(in male participants)

Tertile 1

Ref.

Ref.

Tertile 2

0.47 (0.24, 0.92)

0.97 (0.49, 1.92)

Tertile 3

0.68 (0.37, 1.24)

1.11 (0.51, 2.42)

Increase per 1 SD

0.78 (0.60, 1.03)

1.15 (0.82, 1.62)

Allcause mortality^{┼}

Tertile 1

Ref.

Ref.

Tertile 2

0.90 (0.74, 1.11)

0.99 (0.80, 1.22)

Tertile 3

1.14 (0.93, 1.41)

1.17 (0.93, 1.47)

Increase per 1 SD

1.03 (0.94, 1.12)

1.08 (0.98, 1.18)

Cancer mortality^{┼}

Tertile 1

Ref.

Ref.

Tertile 2

0.91 (0.69, 1.20)

0.87 (0.66, 1.16)

Tertile 3

0.87 (0.65, 1.16)

0.97 (0.71, 1.31)

Increase per 1 SD

0.92 (0.81, 1.05)

1.06 (0.94, 1.20)

CVD mortality^{┼}

Tertile 1

Ref.

Ref.

Tertile 2

0.87 (0.65, 1.16)

1.04 (0.77, 1.40)

Tertile 3

1.23 (0.92, 1.66)

1.28 (0.93, 1.75)

Increase per 1 SD

1.04 (0.92, 1.17)

1.08 (0.95, 1.22)

 Numbers printed in italics: statistically significantly different from 1 (P < 0.05)
 Abbreviations: CI confidence interval, CVD cardiovascular disease, HR hazard ratio, SD standard deviation
 *The Cox regression model was adjusted for age, sex, batch, and leukocyte distribution
 ^{#}Metaanalyzed results from subset I (cohort design, n = 1000), subcohort of subset II (cohort design, n = 548), and subcohort of subset III (cohort design, n = 741)
 ^{†}Metaanalyzed results from subset I (cohort design, n = 1000), subcohort of subset II (cohort design, n = 548), subset III (casecohort design, n = 741; subcohort, n = 80 lung cancer cases, n = 37 colorectal cancer cases), and subset IV (nested casecontrol design, n = 65 lung cancer cases, n = 100 colorectal cancer cases, n = 176 controls)
 ^{‡}Metaanalyzed results from subset I (cohort design, n = 1000), subcohort of subset II (cohort design, n = 548), and subset III (casecohort design, n = 741; subcohort, n = 128 breast cancer cases)
 ^{┼}Metaanalyzed results from subset I (cohort design, n = 1000), subset II (casecohort design, n = 548; subcohort, n = 316 allcause mortality, n = 128 cancer mortality, n = 104 CVD mortality), and subset III (casecohort design, n = 741; subcohort, n = 538 allcause mortality, n = 209 cancer mortality, n = 181 CVD mortality)